Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder.

Chen CK, Lee CS, Chen HY, Wu LS, Chang JC, Liu CY, Cheng AT.

BJPsych Open. 2016 Sep 8;2(5):301-306.

2.

The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.

Oedegaard KJ, Alda M, Anand A, Andreassen OA, Balaraman Y, Berrettini WH, Bhattacharjee A, Brennand KJ, Burdick KE, Calabrese JR, Calkin CV, Claasen A, Coryell WH, Craig D, DeModena A, Frye M, Gage FH, Gao K, Garnham J, Gershon E, Jakobsen P, Leckband SG, McCarthy MJ, McInnis MG, Maihofer AX, Mertens J, Morken G, Nievergelt CM, Nurnberger J, Pham S, Schoeyen H, Shekhtman T, Shilling PD, Szelinger S, Tarwater B, Yao J, Zandi PP, Kelsoe JR.

BMC Psychiatry. 2016 May 5;16:129. doi: 10.1186/s12888-016-0732-x.

3.

Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study.

Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardau R, Arias B, Backlund L, Banzato CE, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Bui ET, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Étain B, Falkai P, Forstner AJ, Frisén L, Fullerton JM, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt S, Wright A, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus EZ, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoroiu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, Rietschel M, McMahon FJ, Schulze TG.

Lancet. 2016 Mar 12;387(10023):1085-93. doi: 10.1016/S0140-6736(16)00143-4.

PMID:
26806518
4.

Emergent treatments based on the pathophysiology of bipolar disorder: A selective review.

Brady RO, Keshavan M.

Asian J Psychiatr. 2015 Dec;18:15-21. doi: 10.1016/j.ajp.2015.07.017. Review.

5.

Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder.

Song J, Bergen SE, Di Florio A, Karlsson R, Charney A, Ruderfer DM, Stahl EA; Members of the International Cohort Collection for Bipolar Disorder (ICCBD)., Chambert KD, Moran JL, Gordon-Smith K, Forty L, Green EK, Jones I, Jones L, Scolnick EM, Sklar P, Smoller JW, Lichtenstein P, Hultman C, Craddock N, Landén M, Smoller JW, Perlis RH, Lee PH, Castro VM, Hoffnagle AG, Sklar P, Stahl EA, Purcell SM, Ruderfer DM, Charney AW, Roussos P, Michele Pato CP, Medeiros H, Sobel J, Craddock N, Jones I, Forty L, Florio AD, Green E, Jones L, Gordon-Smith K, Landen M, Hultman C, Jureus A, Bergen S, McCarroll S, Moran J, Smoller JW, Chambert K, Belliveau RA.

Mol Psychiatry. 2016 Sep;21(9):1290-7. doi: 10.1038/mp.2015.165.

6.

Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.

Alda M.

Mol Psychiatry. 2015 Jun;20(6):661-70. doi: 10.1038/mp.2015.4. Review.

7.

College Students: Mental Health Problems and Treatment Considerations.

Pedrelli P, Nyer M, Yeung A, Zulauf C, Wilens T.

Acad Psychiatry. 2015 Oct;39(5):503-11. doi: 10.1007/s40596-014-0205-9. Review.

8.
9.

Towards the clinical implementation of pharmacogenetics in bipolar disorder.

Salloum NC, McCarthy MJ, Leckband SG, Kelsoe JR.

BMC Med. 2014 May 30;12:90. doi: 10.1186/1741-7015-12-90.

10.

Response to lithium in bipolar disorder: clinical and genetic findings.

Rybakowski JK.

ACS Chem Neurosci. 2014 Jun 18;5(6):413-21. doi: 10.1021/cn5000277. Review.

11.

Molecular actions and clinical pharmacogenetics of lithium therapy.

Can A, Schulze TG, Gould TD.

Pharmacol Biochem Behav. 2014 Aug;123:3-16. doi: 10.1016/j.pbb.2014.02.004. Review.

12.

Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Reynolds GP, McGowan OO, Dalton CF.

Br J Clin Pharmacol. 2014 Apr;77(4):654-72. doi: 10.1111/bcp.12312. Review.

13.

Implications and limitations of cellular reprogramming for psychiatric drug development.

Tobe BT, Brandel MG, Nye JS, Snyder EY.

Exp Mol Med. 2013 Nov 15;45:e59. doi: 10.1038/emm.2013.124. Review.

14.

Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Rybakowski JK.

CNS Drugs. 2013 Mar;27(3):165-73. doi: 10.1007/s40263-013-0040-7. Review.

15.

Predictors of lithium response in bipolar disorder.

Tighe SK, Mahon PB, Potash JB.

Ther Adv Chronic Dis. 2011 May;2(3):209-26. doi: 10.1177/2040622311399173.

16.

Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation.

Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A, Lorberg B, Mane S, Zhao H, Sinha R, Bhagwagar Z, Beech R.

Biol Mood Anxiety Disord. 2012 Sep 12;2:15.

17.

P2RX7: expression responds to sleep deprivation and associates with rapid cycling in bipolar disorder type 1.

Backlund L, Lavebratt C, Frisén L, Nikamo P, Hukic Sudic D, Träskman-Bendz L, Landén M, Edman G, Vawter MP, Ösby U, Schalling M.

PLoS One. 2012;7(8):e43057. doi: 10.1371/journal.pone.0043057.

18.

Convergent functional genomic studies of ω-3 fatty acids in stress reactivity, bipolar disorder and alcoholism.

Le-Niculescu H, Case NJ, Hulvershorn L, Patel SD, Bowker D, Gupta J, Bell R, Edenberg HJ, Tsuang MT, Kuczenski R, Geyer MA, Rodd ZA, Niculescu AB.

Transl Psychiatry. 2011 Apr 26;1:e4. doi: 10.1038/tp.2011.1.

19.

Common DISC1 polymorphisms disrupt Wnt/GSK3β signaling and brain development.

Singh KK, De Rienzo G, Drane L, Mao Y, Flood Z, Madison J, Ferreira M, Bergen S, King C, Sklar P, Sive H, Tsai LH.

Neuron. 2011 Nov 17;72(4):545-58. doi: 10.1016/j.neuron.2011.09.030.

20.

Pharmacogenetics in psychiatry: translating research into clinical practice.

Malhotra AK, Zhang JP, Lencz T.

Mol Psychiatry. 2012 Jul;17(8):760-9. doi: 10.1038/mp.2011.146. Review.

Items per page

Supplemental Content

Support Center